Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

CHMP Adopts Negative Opinion On KYNAMROTM - Quick Facts

Genzyme, a Sanofi company (SNY: Quote), and Isis Pharmaceuticals Inc. (ISIS: Quote), announced the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a negative opinion for its marketing authorization application for KYNAMROTM for the treatment of patients with Homozygous Familial Hypercholesterolaemia. Genzyme plans to request a re-examination of the CHMP Opinion.

An application for KYNAMRO is currently under review by the U.S. FDA.

Click here to receive FREE breaking news email alerts for Genzyme Corp. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stocks are turning in a lackluster performance in early trading on Wednesday after moving sharply higher over the past few sessions. The major averages moved lower at the start of trading but have been lingering near the unchanged line since then. At least 11 people were killed in overnight Israeli air strikes on Gaza. The wife and child of Mohammed Deif, who is on top of Israel's most wanted list, were reportedly killed in the attack. Deif, who lost an eye and limbs in earlier assassination attempts, is the head of Hamas' armed wing - the Qassam Brigades. Hamas leader Mousa Abu Marzouk told media on Wednesday that Israel had targeted Deif Bank of England policymakers split on rate decision this month, for the first time in more than three years as two members said the current economic situation warrant an immediate rate hike from a historic-low. At the August Monetary Policy Committee meeting, Ian McCafferty and Martin Weale sought a quarter-point hike in the bank rate to 0.75 percent.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.